PHILADELPHIA – Patients who experience fatigue during radiotherapy for breast or prostate cancer may be reacting to activation of the proinflammatory cytokine network, a known inflammatory pathway, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Julie Bower, Ph.D., an associate professor in the Department of Psychology and Psychiatry at the University of California, Los Angeles, and colleagues, conducted an observational study among 28 patients with breast cancer and 20 patients with prostate cancer, all early stage. Patients completed questionnaires and provided blood samples so researchers could determine the level of proinflammatory markers.
As expected, there was a strong link between radiotherapy treatment and fatigue. In a new finding, the researchers noted that increases in serum markers of cytokine activity, specifically IL-1 receptor antagonist and C-reactive protein, were also linked with fatigue.
"This study suggests that exposure to radiation is releasing these inflammatory cytokines and that may be contributing to fatigue," said Bower.
Scientists have been studying the role of inflammation in several diseases and have recently made breakthroughs about the link between inflammation and diseases like heart disease, Alzheimer's and cancer. There is growing evidence that inflammation may also contribute to depression and other behavioral disturbances, including fatigue and sleep problems.
Stephen Hahn, M.D., chair of the Department of Radiation Oncology at the Abramson Cancer Center at the University of Pennsylvania, said this study is an important step forward in understanding the biological basis for fatigue.
"Fatigue related to radiotherapy is very common but we do not have any good idea about why it occurs. This suggests one possible mechanism and suggests an avenue for treatment," said Hahn, who is also an editorial board member of Clinical Cancer Research.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
Clinical Cancer Research